S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor.
体内研究:
S19-1035 exhibits inhibitory activity for AKR1C3 with an IC50 value of 3.04 nM. S19-1035 (0-100 μM; 72 h or 96 h) has less cytotoxic and had limited antitumor effects when used alone. S19-1035 (10 μM; 8 days) significantly reversed the doxorubicin (DOX) resistance in a resistant breast cancer cell line in co-administration.